<DOC>
	<DOC>NCT00894322</DOC>
	<brief_summary>This study is designed to evaluate the pharmacokinetics, tolerability, and safety of exenatide once weekly suspension in both healthy subjects and in subjects with type 2 diabetes. The study will also evaluate efficacy in the type 2 diabetes patients. Development of this exenatide once weekly presentation would eliminate the need to reconstitute the product prior to use.</brief_summary>
	<brief_title>A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Cohort 1: Is 19 to 65 years old Has a body mass index (BMI) of 23 kg/m2 to 35 kg/m2, inclusive, at study start Cohort 2: Is 19 to 75 years old Has been diagnosed with type 2 diabetes mellitus Has HbA1c of 7.1% to 10.0%, inclusive, at study start Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at study start Has been treated with diet and exercise alone or with a stable regimen of metformin, a TZD, or a combination of metformin and a TZD, for a minimum of 2 months prior to study start Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to study start: Hormone replacement therapy (female subjects) Oral contraceptives (female subjects) Antihypertensive agents Lipidlowering agents Thyroid replacement therapy Antidepressant agents Cohort 1: Has a personal history of diabetes mellitus (including impaired glucose tolerance, impaired fasting glucose, or gestational diabetes) Has received any investigational drug within 30 days (or 5 halflives of the investigational drug, whichever is greater) prior to study start Has ever been exposed to exenatide (BYETTA, exenatide once weekly, or any other formulation of exenatide) or any GLP 1 analog Cohort 2: Has received any investigational drug within 30 days (or 5 halflives of the investigational drug, whichever is greater) prior to study start Has ever been exposed to exenatide (BYETTA, exenatide once weekly, or any other formulation of exenatide) or any GLP 1 analog Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatmentexcluded medications: Any DPP4 inhibitor or sulfonylurea (SU) within 3 months prior to study start Alpha glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days prior to study start Insulin within 2 weeks prior to study start or for more than 1 week within 3 months prior to study start Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption Prescription or overthecounter weight loss medications within 3 months prior to study start</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide once weekly</keyword>
	<keyword>Byetta</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>